Corning Incorporated (NYSE: GLW) and Pfizer Inc. (NYSE: PFE) today announced the execution of a long-term purchase and supply agreement for Corning Valor^® Glass.

The multiyear agreement provides for the supply of Valor Glass vials to a portion of currently marketed Pfizer drug products.

Since first launching its collaboration with Corning, Pfizer has continued to evaluate Valor Glass’ performance across several aseptic sites, utilizing multiple vial sizes, with a broad range of drug products from Pfizer’s sterile injectables portfolio. During this time, Valor Glass was accepted into and provisionally evaluated under the Food and Drug Administration’s (FDA) Emerging Technology Program.  

“Pfizer Global Supply colleagues directly deliver on our purpose – breakthroughs that change patients’ lives – and those breakthroughs can come in many forms,” said Mike McDermott, president, Pfizer Global Supply. “Our collaboration with Corning is one example of how we continually evaluate new technologies and innovations that have the potential to advance our manufacturing reliability and efficiency.”